| A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism (NCT07284043) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2025-11-27 |
| Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism (NCT07122401) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2025-09-30 |
| Phase I Study of MT1011 Injection in Healthy Subjects (NCT07024160) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2025-06-25 |
| MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease (NCT06690242) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2024-11-04 |
| Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis (NCT06976177) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2024-06-07 |
| A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects (NCT05948774) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2023-07-11 |
| A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism (NCT06747247) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2023-04-07 |
| Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics (NCT05323136) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2022-04-15 |
| MT1013 Clinical TRIAL In Healthy Subject (NCT04783090) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2021-06-28 |
| MT1002 Phase II Study in ACS Patients With PCI (NCT04723186) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2020-12-02 |
| Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection (NCT04116840) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2019-04-29 |